Catalent (CTLT)
(Delayed Data from NYSE)
$54.65 USD
-0.32 (-0.58%)
Updated May 23, 2024 04:00 PM ET
After-Market: $54.65 0.00 (0.00%) 5:16 PM ET
2-Buy of 5 2
C Value F Growth D Momentum F VGM
Brokerage Reports
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 81 - 100 ( 215 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Early FY23 Guidance Shows Path Beyond COVID
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Bioproduction: Catalent''s $350M Indiana Expansion Signals Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
2022 Life Sciences and MedTech Conference: Day 2 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Growth Exceeds; Nuggets Around COVID, 483, Cell Therapy Outlook; Read-Throughs
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Goldilocks Ignored - JPM Week and Implications for Coverage List
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Transformational Year Validating Higher Industry Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Wegovy for Novo Nordisk Appears Immaterial and No Vaccine/ Therapy Implications
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Quarter in Line, but Healthy (Higher Guide) Outlook Ahead
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department